Zhejiang Longcharm Biomedical Technology

Zhejiang Longcharm Biomedical Technology, established in 2016 and headquartered in Hangzhou, China, is a biopharmaceutical company and contract research organization (CRO) specializing in innovative drug development and R&D outsourcing services. The company provides comprehensive services including BA/BE/PK clinical testing, biological analysis, and preclinical research, supported by nearly 5,000 square meters of laboratory facilities. Longcharm's internal pipeline features two clinical-stage innovative drugs in oncology, most notably LC004, a third-generation non-covalent BTK inhibitor currently in Phase 1/2 trials for B-cell malignancies. The company also focuses on advanced technologies such as nucleic acid delivery (mRNA/siRNA) and ADME improvement, and has developed specialized humanized mouse models for Alpha-1 antitrypsin deficiency (AATD). Longcharm is closely affiliated with Zhejiang Puli Pharmaceutical and has successfully passed multiple FDA inspections, demonstrating its commitment to international quality standards.